CADL

NASDAQ Healthcare

Candel Therapeutics, Inc. - Common Stock

Biotechnology

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

๐Ÿ“Š Market Data
Price$6.47
Volume1,588,995
Market Cap474.06M
Beta-0.810
RSI (14-Day)68.3
200-Day MA$5.55
50-Day MA$5.34
52-Week High$7.66
52-Week Low$4.34
Forward P/E-10.11
Price / Book6.84
๐ŸŽฏ Investment Strategy Scores

CADL scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 39/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿ”ช Falling Knife 20/100โ–ผ -8
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 79/100โ–ฒ +7
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐ŸŽˆ Over-Hyped (79/100) โ€” this strategy Overbought stocks (potential short candidates).

Lowest fit among scored strategies: ๐Ÿ‹ Institutional Whale (12/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find CADL in your text

Paste any article, transcript, or post โ€” the tool will extract CADL and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.